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Abstract
AIM
To evaluate the effects of the non-selective, non-steroidal 
anti-inflammatory drug (NSAID) acetylsalicylic acid (ASA), 
on ex vivo  embryonic kidney growth and development. 
METHODS
Pairs of fetal mouse kidneys at embryonic day 12.5 were 
cultured ex vivo  in increasing concentrations of ASA 
(0.04-0.4 mg/mL) for up to 7 d. One organ from each 
pair was grown in control media and was used as the 
internal control for the experimental contralateral organ. 
In some experiments, organs were treated with ASA for 
48 h and then transferred either to control media alone 
or control media containing 10 µmol/L prostaglandin E2 
(PGE2) for a further 5 d. Fetal kidneys were additionally 
obtained from prostaglandin synthase 2 homozygous null 
or heterozygous (PTGS2-/- and PTGS2-/+) embryos and 
grown in culture. Kidney cross-sectional area was used 
to determine treatment effects on kidney growth. Whole-
mount labelling to fluorescently detect laminin enabled 
crude determination of epithelial branching using confocal 
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microscopy. 
RESULTS
Increasing ASA concentration (0.1, 0.2 and 0.4 mg/mL) 
significantly inhibited metanephric growth (P  < 0.05). 
After 7 d of culture, exposure to 0.2 mg/mL and 0.4 
mg/mL reduced organ size to 53% and 23% of control 
organ size respectively (P  < 0.01). Addition of 10 µmol/L 
PGE2 to culture media after exposure to 0.2 mg/mL ASA 
for 48 h resulted in a return of growth area to control 
levels. Application of control media alone after cessation 
of ASA exposure showed no benefit on kidney growth. 
Despite the apparent recovery of growth area with 10 
µmol/L PGE2, no obvious renal tubular structures were 
formed. The number of epithelial tips generated after 48 
h exposure to ASA was reduced by 40% (0.2 mg/mL; P 
< 0.05) and 47% (0.4 mg/mL; P  < 0.01). Finally, growth 
of PTGS2-/- and PTGS2+/- kidneys in organ culture showed 
no differences, indicating that PTGS2 derived PGE2 may at 
best have a minor role. 
CONCLUSION
ASA reduces early renal growth and development but 
the role of prostaglandins in this may be minor. 
Key words: Acetylsalicylic acid; Nephrogenesis; Kidney 
culture; Non-steroidal anti-inflammatory drug; Prostaglandins; 
Prostaglandin synthase 2
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Non-steroidal anti-inflammatory drugs (NSAIDs) 
are widely used as painkillers and are available without 
prescription. They act by inhibiting cyclooxygenase 
activity thereby preventing prostaglandin synthesis via 
the prostaglandin synthase enzymes prostaglandin 
synthase 1 (PTGS1) and PTGS2. Although NSAIDs cross 
the placenta, they are among the most common drugs 
prescribed during the first trimester of pregnancy and 
estimated prevalence of usage is more than 25% of 
pregnant women. NSAID use during pregnancy has been 
associated with abnormal renal development and renal 
failure in the offspring at birth. These may impact the 
individual throughout their adult life. 
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INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) such 
as aspirin and ibuprofen are commonly used analgesics 
for the treatment of low-grade pain and inflammation. 
NSAIDs are available without prescription and are 
frequently taken during pregnancy[1]. Up to 25% of 
women self-prescribe NSAIDs to treat common ailments 
during pregnancy[2-4]. Although there is clear evidence 
to suggest that aspirin and other NSAIDs can cross the 
placenta, recent research on aspirin use in pregnancy 
has largely been based on the examination of structural 
birth defects as an outcome[5-7]. The key findings from 
these studies were that NSAID use during pregnancy 
does not appear to be a major risk factor for inducing 
birth defects. However, potentially more subtle effects of 
maternal NSAID consumption on fetal tissue and organ 
development have received little attention.
NSAIDs act by inhibition of cyclooxygenase enzymes 
which catalyse the conversion of arachidonic acid to 
prostaglandins. Two isoforms exist, prostaglandin 
synthase 1 (PTGS1) and prostaglandin synthase 2 
(PTGS2). Although they share a very similar structure 
they differ in their pattern of regulation and physiological 
function[8]. PTGS1 is expressed constitutively in most 
tissues and is thought to have a cellular “housekeeping” 
and cytoprotective role[9]. In contrast, PTGS2 is induced 
as a result of an inflammatory response in most 
tissues[10], but is constitutively expressed in the fetal and 
adult kidney[11], highlighting the role for PTGS2 derived 
prostaglandins in adult kidney function and suggesting a 
role in kidney development. 
Fetal rat kidneys can synthesise prostaglandins 
prostaglandin E2 (PGE2), PGD2, PGI2, and PGF2α, as well as 
thromboxanes and leukotrienes[12,13]. This corresponds to 
intense PTGS2 immunoreactivity and mRNA expression 
in a subset of thick ascending limb epithelial cells near 
the macula densa in developing nephrons suggesting 
a role for PTGS2 derivatives in the maturation and/or 
early function of nephrons[14]. Disruption of prostaglandin 
synthesis during early renal development through PTGS2 
inhibition suggests that prostaglandins may be required 
for normal renal development[15-17]. PTGS2 knockout mice 
exhibit a severe reduction in the number of nephrons[16] 
and postnatally are observed to possess many immature 
glomeruli and tubules as well as a thinner outer cortex[18]. 
PTGS2 inhibitors, such as Aspirin, impair glomerulo-
genesis during gestation[19]. Clinical studies have revealed 
various abnormalities such as renal maldevelopment and 
renal non function syndrome in newborns of mothers 
treated with NSAIDs during pregnancy[20,21]. Histological 
analysis of the kidneys revealed crowded glomeruli and 
few differentiated proximal tubules in the inner cortex[20]. 
Long term effects of NSAID administration during 
pregnancy reveal structural and functional abnormalities 
in the rodent kidney. Ultra-structural changes in fetal 
glomeruli in rats treated with indomethacin were demon-
strated by Sessa et al[22], in the form of enlarged Golgi. A 
further study provides evidence that chronic administration 
of indomethacin to pregnant rhesus monkeys also causes 
neonatal renal hypoplasia decreasing kidney mass by 
15%[23]. 
Evidence from PTGS2-/- mice, however, suggests that 
the role of prostaglandins in renal development is most 
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likely to be during postnatal maturation in these animals. 
PTGS2-/- mice have apparently normal kidneys at birth, 
but subsequently exhibit developmental impairment 
in the postnatal period immediately prior to the final 
termination of development. This suggests either that 
the role for prostaglandins derived from PTGS2 in renal 
development is only during this short postnatal stage of 
maturation, or that sufficient prostaglandins are obtained 
exogenously from the mother prior to birth.
In this study, we examined the requirement for pros-
taglandin production on early kidney development using 
global blockade with acetyl-salicylic acid (ASA). We show 
a significant and terminal detrimental effect on growth of 
ex-vivo fetal mouse kidneys after exposure to ASA and 
further that this effect is likely to be independent of the 
inhibition of prostaglandin generation from the PTGS2 
gene due to successful culture of PTGS2-/- organs.
MATERIALS AND METHODS
Reagents
All reagents were purchased from Sigma-Aldrich chemical 
company (Poole, Dorset, United Kingdom) unless 
otherwise stated.
Generation of timed pregnancies
The present investigation was performed in accordance 
with the Home Office Guidance on the operation of 
the Animals (Scientific Procedures) Act (Great Britain 
Home Office, 2000). Outbred ICR (Institute for Cancer 
Research) mice were maintained on a 12-h light-dark 
cycle with free access to standard laboratory chow and 
water. Male and female mice were housed together and 
embryonic day 0.5 (E0.5) was designated upon detection 
of a vaginal plug, indicating mating, on the floor of the 
cage. Litters were removed 12 d after plugging. Whole 
metanephroi were micro-dissected from the E12.5 
embryos under sterile conditions, at which point, they 
were termed Day 0 for ex vivo studies (Barak and Boyle 
2011). Ethical approval for this study was provided by 
the University of Nottingham’s local Animal Welfare and 
Ethical Review Board.
Culture of isolated whole embryonic kidneys
Fetal kidneys were cultured individually on Millicell inserts 
(12 mm diameter, 0.4 µm pore; Millipore Corporation, 
Billerica, MA, United States) in 24-well culture plates with 
DMEM F-12 media supplemented with penicillin (100 
U/mL), streptomycin (100 µg/mL), insulin (10 mg/L), 
sodium selenite (5 g/L), and transferrin (5.5 mg/L) at 
37 ℃ in a humidified atmosphere of air-5% CO2 for up to 
7 d. Media was changed every 24-48 h. For experimental 
NSAID treatment, DMEM media was supplemented with 
0.04 mg/mL (0.2 mmol/L), 0.1 mg/mL (0.56 mmol/L), 
0.2 mg/mL (1.1 mmol/L) or 0.4 mg/ml (2.2 mmol/L) 
acetyl salicylic acid (ASA; aspirin) in line with other in 
vitro studies[24-27].
Recovery experiments included 48 h pre-treatment 
with 0.2 mg/mL ASA before replacing with control 
media or media supplemented with 10 µmol/L PGE2  
from day 3-7. All metanephroi that were treated with 
ASA and or PGE2 were compared to their untreated 
contra-lateral controls for analysis.
Imaging and measurements
During 7 d of culture, metanephros growth was monitored 
and recorded every 24 h using a Leica DMIL microscope 
[Leica Microsystems Ltd, Milton Keynes, Bucks, United 
Kingdom] fitted with a Leica DFC420C digital camera. 
Cross-sectional areas of whole metanephroi were deter-
mined using Image Pro Plus v5.1 (Media Cybernetics, 
Corporation, Silver Spring, MD, United States). A free-
hand drawing tool was used to precisely draw around 
each metanephros and calculate the total cross-sectional 
surface area. Cross sectional surface area measurements 
were converted to µm2 (using micrometer validation) 
and metanephroi treated with ASA and or PGE2 were 
compared with their untreated contralateral controls. 
Whole-mount immunofluorescence
Kidneys were fixed in 4% PFA in PBS for 20 min, washed 
in PBS, permeabilised in 0.2% triton X 100 in PBS 
overnight at 4 ℃. All 4 ℃ incubation steps were carried 
out with rolling. Antibodies were diluted in PBS. Organs 
were washed in PBS incubated with the primary antibody 
against laminin (L9393, Sigma; incubated at 1:100 
dilution) overnight at 4 ℃. Kidneys were washed in PBS 
and incubated with secondary antibody (Anti-Rabbit IgG, 
FITC F0205, Dako UK Ltd; incubated at 1:20 dilution) 
overnight at 4 ℃. Finally, organs were washed three 
times in PBS and mounted on slides (pre-prepared with 
a ring of hardened DPX to preserve the 3D structure of 
the kidney) in Vectashield Hardset (Vector Laboratories). 
Organs were imaged using a confocal microscope [Leica 
Microsystems (UK) Ltd, Milton Keynes, Bucks, United 
Kingdom].
Statistical analysis 
Statistical analysis was performed using SPSS version 
16. Growth data were analysed with day of culture (0 = 
baseline, day 1 and day 2) as a repeated measure with 
genotype as a fixed effect in the model. Nested effects 
in the model, e.g., siblings (males and females) from the 
same litter and paired organs from the same individual 
(left kidney = control, right kidney = treated) were 
accounted for in the model as random effects (litterID/
pupID). Analysis of data at single time points was by 
one-way ANOVA, blocking for individual ID. Results are 
presented as means ± SEM with aP ≤ 0.05 considered 
statistically significant. Letters are used throughout to 
represent statistical differences as follows; bP < 0.01 and 
dP < 0.005. 
RESULTS
Effect of ASA on growth of E12.5 mouse kidneys
E12.5 mouse kidneys were cultured for seven days in 
the presence or absence of ASA. Control organs grew 
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robustly over the course of 7 d, increasing in size by 
more than 3.5 fold (386%; Figure 1). Incubation in ASA 
at 0.04 mg/mL did not affect organ growth, however 
incubation in concentrations of ASA above 0.04 mg/mL 
resulted in increasingly severe growth impairment (Figure 
1). Growth of kidneys exposed to 0.2 mg/mL ASA was 
significantly reduced by day 3 of treatment and organs 
remained growth impaired for the duration of culture (P 
< 0.05; Figure 1). Doubling the concentration of ASA to 
0.4 mg/mL led to more severe growth restriction by as 
early as 24 h of culture (P < 0.05; Figure 1). Continued 
exposure to ASA (> 0.04 mg/mL) beyond three days of 
culture consistently resulted in organ disintegration by 
day 7.
We assessed the influence of ASA on branching 
morphogenesis by counting the generation of epithelial 
tips in organs labelled to detect laminin (Figure 2). We 
found that the number of observable epithelial tips was 
reduced by 40% and 43% after exposure to ASA for 
2 d at concentrations of 0.2 mg/mL and 0.4 mg/mL 
respectively (P < 0.005).
Effect of prostaglandins on the adverse actions of ASA
To determine whether the adverse effects of ASA on early 
renal development could be reversed, embryonic kidneys 
were cultured in the presence of either 0.2 mg/mL or 
0.4 mg/mL ASA for 48 h and subsequently returned to 
control media or media containing PGE2 (10 µmol/L), 
or PGE2 combined with 0.2 mg/mL or 0.4 mg/mL ASA 
during days 2-7 of culture. As expected, exposure to ASA 
for 48 h (culture days 0-2) blunted embryonic kidney 
growth compared with their untreated contralateral 
kidneys (P < 0.05; Figure 3A and B). Replacement of 
ASA containing media with control culture media (for 
days 0-2) resulted in a small increase in size. However, 
kidneys still remained significantly smaller than con-
tralateral controls for each day of culture (days 2-7; 
Figure 3A and B). Embryonic kidneys exposed to ASA for 
48 h and subsequently treated with 10 µmol/L PGE2 in 
control media (for culture days 2-7) grew more quickly 
than those in control media alone (Figure 3C and D) such 
that by culture day 7 their cross-sectional areas matched 
contra-lateral control kidneys. Nevertheless, despite 
recovery of growth of kidneys by PGE2 the kidneys 
remained structurally immature, lacking developing 
tubules observed in controls. In addition, the blunted 
growth of ASA treated kidneys grown in culture media 
containing both PGE2 and ASA from days 2-7, were 
significantly smaller than their contra-lateral controls and 
failed to increase in size throughout the culture period (P 
< 0.05). These experiments suggested that blockade of 
prostaglandins by ASA may have permanent detrimental 
consequences for fetal kidney growth. 
Therefore, to determine if the growth impairment 
seen in the presence of ASA might indicate a requirement 
for PTGS2 derived prostanoids, we cultured kidneys from 
PTGS2 null (PTGS2-/-) or PTGS2 heterozygous (PTGS2-/+) 
mice. Growth of organs from PTGS2-/- and PTGS2-/+ mice 
(n = 3 for each group including contralaterals as internal 
controls) were unaffected by genotype, increasing by 
74% ± 11% vs 62% ± 13% respectively after 48 h (P = 
0.13). Size of organs was comparable at all time points 
with those from wild type ICR mice. 
DISCUSSION
In this study we have demonstrated that exposure of 
the developing kidney to aspirin impairs overall growth. 
Such impairment of growth suggested at best a minor 
role for prostaglandins, as organs examined ex-vivo from 
mice genetically manipulated to prevent prostaglandin 
production (PTGS2-/-) were able to grow similarly to 
kidneys from control mice.
PTGS1-/- mice exhibit no renal phenotype[28] and 
PTGS2-/- mice only appear to show evidence of renal 
malformation during postnatal life[19]. This has been 
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Figure 1  Growth curves for cross section area for acetylsalicylic acid treatments. Cross-section metanephroi area was used to produce growth curves of 
individual ASA treatments and their contralateral controls (n = 8-12). Controls are represents together as there were no differences between controls of each treatment 
group. aP < 0.05, bP < 0.005 denotes statistical differences with control organs. ASA: Acetylsalicylic acid.
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suggested to indicate that there may be little or no 
requirement for prostaglandins in the early (fetal) stages 
of kidney development, however this does not preclude 
the possibility that maternally derived prostanoids replace 
those otherwise acquired from endogenous production. 
The role PTGS derived products play in controlling 
embryonic and organ growth has been previously 
explored. Incubation of cultured whole rat embryos 
with the PTGS1/2 inhibitor ASA or Indomethacin for 
48 h exhibited dysmorphogenesis. Furthermore, the 
teratogenic effects of each inhibitor were diminished 
following PGE2 supplementation[29]. Mice and rats treated 
with PTGS2 selective inhibitors throughout pregnancy 
produce offspring with kidneys which exhibit impaired 
development similar to that observed in PTGS2 knockout 
mice, including reduced glomerular diameter and the 
presence of numerous immature glomeruli[19]. However, 
this was only apparent when administration was con-
tinued during the postnatal period until weaning at 
P21. When organs were examined at P0, there was no 
difference between any of the groups. In addition, the 
authors found no effect of administration of the PTGS1 
selective inhibitor SC58560 at any stage in development. 
A reduction in the nephrogenic zone following PTGS2 
inhibition was observed in the study by Komhoff[19] and 
by PTGS1 and 2 inhibition in preterm baboons treated 
with ibuprofen to pharmacologically close the ductus 
arteriosus[30]. A reduction in nephrogenic zone growth is 
suggestive of either an early cessation of nephrogenesis 
and or premature renal maturation. These adverse 
effects of PTGS1/2 inhibition may result in a nephron 
deficit, and have detrimental consequences on renal 
health in later life[31]. 
We did not determine the identity of the cells which 
were most affected in our experiments, so are unable 
to make a specific statement about the population of 
nephrogenic precursors. However, we would speculate 
that reduction in the population of nephron progenitors 
would significantly hamper further development[32]. An 
important factor with regard to the phenotype most 
normally observed after PTGS inhibition is that the final 
glomeruli to be formed are immature and very closely 
apposed to the underside of the renal capsule. This is 
not necessarily something that would be observed as a 
result of a reduced population of nephron precursors. It 
rather argues in favour of an impairment of maturation 
of the vasculature. This might not be all that surprising 
considering the final location of the PTGS2 in the adult 
kidney and its requirement for vasodilation[33].
Long term use of NSAIDS can restrict blood flow to 
such an extent in the kidney that these organs exhibit 
phenotypic changes reminiscent of ischemic damage[33,34]. 
It seems possible that the ability to vasodilate the 
developing afferent arterioles is potentially a requirement 
for the final stages of glomerular maturation. Assessment 
of this role may require grafting of developing organs 
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onto an external vasculature or the use of a carefully 
targeted mouse mutant possessing loci enabling 
deletion of PTGS2 within the afferent arteriole which 
may be regulated by exogenous means (i.e., temporal 
application of tamoxifen). This would potentially enable 
deletion of PTGS2 from some groups of arterioles and 
not others, labelling of those arterioles and examination 
of the influence of the loss of PTGS2 on the development 
of their associated glomeruli.
Whilst we show there to be no influence of genotype 
on the ability to grow in organ culture, we did not 
include wild-type litter mates in the culture system. 
Instead we used heterozygotes as controls. Recently 
published work[35] has demonstrated that there is in 
fact an influence of the reduction of gene dosage on 
renal structural and functional outcome. However, the 
differences compared with wild-type, whilst significant 
were relatively small and differed greatly with those 
seen in homozygotes. Therefore, although we cannot 
definitively state that our experiments show there to be 
no influence of a loss of PGTS2 on fetal renal growth in 
ex-vivo culture, we are reasonably confident that this is 
indeed the case. 
Limitations of the study
As has been mentioned above, we were unable to 
perform detailed analysis of the cell types most influenced 
by exposure to ASA. Such information would be par-
ticularly helpful in establishing the specific mechanism 
by which ASA impairs early organogenesis, particularly 
since this appears to be prostaglandin independent 
and therefore occurs via a process distinct from organ 
disruption seen by PTGS2 deletion. Additionally, the 
data presented here are exclusively derived from organ 
explant culture experiments and therefore may not be 
wholly reflective of the process of renal developmental 
impairment seen in vivo after overconsumption of ASA or 
similar NSAIDs. Future studies will be required to address 
these issues in order to clarify the precise pathways of 
damage and the specific relevance to humans. 
In conclusion, the work we describe in this study 
adds to the wider data which suggests that, for early 
kidney development, there is no specific requirement 
for prostaglandins. Kidneys from animals lacking 
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PTGS2 grew entirely normally in ex vivo culture without 
the requirement for exogenous prostaglandins. This 
strongly suggests that fetal renal development does not 
require inducible prostaglandin production. We cannot 
entirely rule out a requirement for other prostaglandins 
in these studies since the PTGS2-/- organs will still 
have retained PTGS1 expression, however, since no 
demonstration of its requirement for renal development 
has been identified[28] we would suggest that our data 
argue against a role for prostaglandins in mediating 
nephrogenesis in the fetus. Our data further suggests 
that the impairment of growth induced by exposure of 
organs to ASA in ex vivo culture is likely due to factors 
independent of their ability to produce prostaglandins. 
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of damage might be active. The apparent requirement for PGs during final 
maturation may suggest that PG mediated vasodilation within the final stages of 
tubular development is needed to permit glomerular maturation.
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In addition, the work here clarifies the need to establish the non-PG effects of 
NSAIDs on renal maturation. By understanding these two aspects of NSAID 
treatment/loss of PG production or signalling, may help to modify treatments 
particularly for premature infants faced with a requirement to receive NSAIDs.
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